Amivantamab
Showing 1 - 25 of 26
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
NSCLC Trial in Houston (Amivantamab, Tepotinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- Amivantamab
- Tepotinib
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +6 more
- (no location specified)
Nov 7, 2023
NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Osimertinib
- Amivantamab
- (no location specified)
Mar 24, 2023
NSCLC Trial in Korea, Republic of, Malaysia, United States (Cetrelimab, Amivantamab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cetrelimab
- Amivantamab
-
Fairfax, Virginia
- +3 more
Jun 16, 2023
Salivary Gland Cancer Trial in Cincinnati (Amivantamab)
Recruiting
- Salivary Gland Cancer
- Amivantamab
-
Cincinnati, OhioUniversity of Cincinnati Medical Center
Aug 5, 2022
Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- Amivantamab
- +3 more
- (no location specified)
Oct 30, 2023
Stomach Tumors, Esophageal Tumors Trial in Japan (Amivantamab)
Recruiting
- Stomach Neoplasms
- Esophageal Neoplasms
- Amivantamab
-
Chuo-Ku, Japan
- +10 more
Jan 27, 2023
Esophagogastric Cancer Trial in United States (Amivantamab)
Recruiting
- Esophagogastric Cancer
- Amivantamab
-
Boston, Massachusetts
- +7 more
Oct 24, 2022
NSCLC Trial in Worldwide (Dexamethasone, Montelukast, Methotrexate)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Dexamethasone
- +4 more
-
Fountain Valley, California
- +17 more
Jan 31, 2023
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer Trial in United States (Amivantamab, Lazertinib)
Recruiting
- Metastatic Non Small Cell Lung Cancer
- Recurrent Non Small Cell Lung Cancer
- Amivantamab
- Lazertinib
-
Basking Ridge, New Jersey
- +6 more
Aug 1, 2022
Carcinoma, Hepatocellular Trial in China (Amivantamab)
Recruiting
- Carcinoma, Hepatocellular
- Amivantamab
-
Beijing, China
- +15 more
Jan 27, 2023
Advanced Solid Malignancies Trial in Worldwide (Ami-LC-MD, Ami-LC, Ami-HC)
Recruiting
- Advanced Solid Malignancies
- Ami-LC-MD
- +4 more
-
West Hollywood, California
- +13 more
Jan 31, 2023
Non Small Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Zirabev)
Not yet recruiting
- Non Small Cell Lung Cancer
- Amivantamab
- +2 more
-
Angers, France
- +30 more
Oct 31, 2022
Metastatic NSCLC Trial (Amivantamab)
Approved for marketing
- Metastatic Non-Small Cell Lung Cancer
- Amivantamab
- (no location specified)
Jun 28, 2021
NSCLC Trial in Worldwide (Capmatinib, Amivantamab)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Capmatinib
- Amivantamab
-
Orange, California
- +40 more
Aug 3, 2022
Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)
Not yet recruiting
- Carcinoma, Non-small-Cell Lung
- Amivantamab
- +3 more
-
Westwood, Kansas
- +47 more
Aug 17, 2022
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer Trial in Huntersville (FT536, Cyclophosphamide, Fludarabine)
Recruiting
- Non Small Cell Lung Cancer
- +6 more
- FT536
- +10 more
-
Scottsdale, Arizona
- +4 more
Dec 27, 2022
Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Lazertinib, Amivantamab Subcutaneous and Co-Formulated with
Recruiting
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lazertinib
- +2 more
-
Duarte, California
- +208 more
Jan 31, 2023
Advanced or Metastatic Colorectal Cancer Trial in Worldwide (Amivantamab, Fluorouracil, Leucovorin)
Recruiting
- Advanced or Metastatic Colorectal Cancer
- Amivantamab
- +4 more
-
Birmingham, Alabama
- +85 more
Jan 27, 2023
Non-Small-Cell Lung Cancer Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)
Recruiting
- Non-Small-Cell Lung Cancer
- Amivantamab
- +3 more
-
Duarte, California
- +100 more
Jan 31, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Los Angeles, California
- +83 more
Jan 31, 2023
NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +2 more
-
Duarte, California
- +228 more
Jan 31, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Phoenix, Arizona
- +303 more
Aug 17, 2022
NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +3 more
-
Goodyear, Arizona
- +266 more
Aug 17, 2022